Effect of interleukin-2 on long term infusion treatment regimen of ch14.18/CHO antibody on activity in relapsed/refractory neuroblastoma patients.

被引：0
|
作者：
Loibner, Hans
Siebert, Nikolai
Eger, Christin
Janzek, Evelyne
Ladenstein, Ruth
Lode, Holger N.
机构：
[1] Apeiron Biol AG, Vienna, Austria
[2] Univ Med Greifswald, Greifswald, Germany
[3] Apeiron Biol, Vienna, Austria
[4] St Anna Childrens Hosp & Res Inst, Paediat Haematol Oncol, SIOP Europe Neuroblastoma Grp, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.10563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10563
引用
收藏
页数：2
相关论文
共 47 条
  • [41] Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304)
    Lode, Holger N.
    Ehlert, Karoline
    Huber, Stephanie
    Siebert, Nikolai
    Troschke-Meurer, Sascha
    Zumpe, Maxi
    Loibner, Hans
    Ladenstein, Ruth Lydia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (sclL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.
    Lode, Holger N.
    Valteau-Couanet, Dominique
    Gray, Juliet
    Luksch, Roberto
    Wieczorek, Aleksandra
    Castel, Victoria
    Ash, Shifra
    Laureys, Genevieve
    Papadakis, Vassilios
    Owens, Cormac
    Garaventa, Alberto
    Manzitti, Carla
    Siebert, Nikolai
    Troschke-Meurer, Sascha
    Glogova, Evgenia
    Poetschger, Ulrike
    Ladenstein, Ruth Lydia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.
    Ladenstein, Ruth Lydia
    Poetschger, Ulrike
    Couanet, Dominique Valteau
    Gray, Juliet
    Luksch, Roberto
    Castel, Victoria
    Ash, Shifra
    Laureys, Genevieve
    Owens, Cormac
    Trahair, Toby
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Schroeder, Henrik
    Popovic, Maja Beck
    Loibner, Hans
    Schreier, Guenter
    Ambros, Peter F.
    Sarnacki, Sabine
    Boterberg, Tom
    Lode, Holger N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] SINGLE AGENT ACTIVITY OF THE ANTI-GD2 ANTIBODY DINUTUXIMAB BETA LONG-TERM INFUSION IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH RELAPSED AND REFRACTORY DISEASE. A MULTICENTER PHASE II TRIAL
    Lode, Holger
    Ehlert, Karoline
    Huber, Stephanie
    Siebert, Nikolai
    Troschke-Meurer, Sascha
    Zumpe, Maxi
    Loibner, Hans
    Ladenstein, Ruth
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [45] Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).
    Ladenstein, Ruth
    Poetschger, Ulrike
    Gray, Juliet
    Valteau-Couanet, Dominique
    Luksch, Roberto
    Castel, Victoria
    Yaniv, Isaac
    Laureys, Genevieve
    Elliott, Martin
    Michon, Jean Marie
    Owens, Cormac
    Trahair, Toby
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Schroeder, Henrik
    Popovic, Maja Beck
    Glogova, Evgenia
    Schreier, Guenter
    Loibner, Hans
    Lode, Holger N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Correlation of killer-cell Ig-like receptor (KIR) haplotypes and Fcy-receptor polymorphisms survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody chi 4.18/CHO.
    Lode, Holger N.
    Troschke-Meurer, Sascha
    Valteau-Couanet, Dominique
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Jensen, Christian
    Eger, Christin
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Loibner, Hans
    Siebert, Nikolai
    Mueller, Ina
    Ladenstein, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.
    Ladenstein, Ruth Lydia
    Poetschger, Ulrike
    Valteau-Couanet, Dominique
    Gray, Juliet
    Luksch, Roberto
    Balwierz, Walentyna
    Castel, Victoria
    Ash, Shifra
    Popovic, Maja Beck
    Laureys, Genevieve
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Vettenranta, Kim
    Owens, Cormac
    Schroeder, Henrik
    Loibner, Hans
    Ambros, Peter F.
    Sarnacki, Sabine
    Boterberg, Tom
    Lode, Holger N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345